GSK to acquire potential asset for multiple myeloma
GSK has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter Phase I trials in 2027. TCEs have shown… Read More